{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:09:06Z","timestamp":1787972946081,"version":"build-2784847793"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ejphar.2023.175720","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T23:52:25Z","timestamp":1681257145000},"page":"175720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function"],"prefix":"10.1016","volume":"949","author":[{"given":"Deepika","family":"Dasari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srashti Gopal","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuhya","family":"Penmetsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmarajan","family":"Sriram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1892-6875","authenticated-orcid":false,"given":"Arti","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejphar.2023.175720_bib1","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s11010-022-04411-6","article-title":"Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression","volume":"477","author":"Abdulrahman","year":"2022","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175720_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-019-0980-4","article-title":"Sodium-glucose cotransporter 2 inhibitor dapagliflozin attenuates diabetic cardiomyopathy","volume":"19","author":"Arow","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"issue":"4","key":"10.1016\/j.ejphar.2023.175720_bib3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jacc.2005.09.050","article-title":"The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy","volume":"47","author":"Asbun","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175720_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cvr\/cvp190","article-title":"SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states","volume":"84","author":"Banerjee","year":"2009","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175720_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01208-z","article-title":"Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF","volume":"20","author":"Bode","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"5","key":"10.1016\/j.ejphar.2023.175720_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ijcp.12948","article-title":"Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus","volume":"71","author":"Budoff","year":"2017","journal-title":"Int. J. Clin. Pract."},{"issue":"3","key":"10.1016\/j.ejphar.2023.175720_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1385\/CT:3:3:219","article-title":"Cell death and diabetic cardiomyopathy","volume":"3","author":"Cai","year":"2003","journal-title":"Cardiovasc. Toxicol."},{"issue":"6","key":"10.1016\/j.ejphar.2023.175720_bib8","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/diabetes.51.6.1938","article-title":"Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome c-mediated caspase-3 activation pathway","volume":"51","author":"Cai","year":"2002","journal-title":"Diabetes"},{"issue":"January","key":"10.1016\/j.ejphar.2023.175720_bib9","first-page":"S125","article-title":"Cardiovascular disease and risk management: standards of medical care in diabetesd 2021","volume":"44","author":"Care","year":"2021","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ejphar.2023.175720_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1021\/acsptsci.1c00207","article-title":"Canagliflozin and dapagliflozin attenuate glucolipotoxicity-induced oxidative stress and apoptosis in cardiomyocytes via inhibition of sodium-glucose cotransporter-1","volume":"5","author":"Dasari","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"SEP","key":"10.1016\/j.ejphar.2023.175720_bib11","first-page":"1","article-title":"Myocyte [Na+]i dysregulation in heart failure and diabetic cardiomyopathy","volume":"9","author":"Despa","year":"2018","journal-title":"Front. Physiol."},{"issue":"October","key":"10.1016\/j.ejphar.2023.175720_bib12","first-page":"1","article-title":"Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy","volume":"13","author":"Du","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.ejphar.2023.175720_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2337\/diaclin.29.3.116","article-title":"Microvascular and macrovascular complications of diabetes","volume":"29","author":"Fowler","year":"2011","journal-title":"Clin. Diabetes"},{"issue":"2","key":"10.1016\/j.ejphar.2023.175720_bib14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/01.ATV.21.2.282","article-title":"Proatherogenic role of elevated CE transfer from HDL to VLDL1 and dense LDL Ia type 2 diabetes impact of the degree of triglyceridemia","volume":"21","author":"Gu\u00e9rin","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.ejphar.2023.175720_bib15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrendo.2015.216","article-title":"Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy","volume":"12","author":"Jia","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"issue":"12","key":"10.1016\/j.ejphar.2023.175720_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11122500","article-title":"The importance of SGLT-2 inhibitors as both the prevention and the treatment of diabetic cardiomyopathy","volume":"11","author":"Kowalska","year":"2022","journal-title":"Antioxidants"},{"issue":"1","key":"10.1016\/j.ejphar.2023.175720_bib17","article-title":"Sodium glucose cotransporter 1 (SGLT1) inhibitors in cardiovascular protection: mechanism progresses and challenges","volume":"176","author":"Li","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"June","key":"10.1016\/j.ejphar.2023.175720_bib18","first-page":"1","article-title":"SGLT1 knockdown attenuates cardiac fibroblast activation in diabetic cardiac fibrosis","volume":"12","author":"Lin","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"January","key":"10.1016\/j.ejphar.2023.175720_bib19","first-page":"1","article-title":"SGLT1 inhibition attenuates apoptosis in diabetic cardiomyopathy via the JNK and P38 pathway","volume":"11","author":"Lin","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2023.175720_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom12020272","article-title":"Glycemic control and the heart: the tale of diabetic cardiomyopathy continues","volume":"12","author":"Longo","year":"2022","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/j.ejphar.2023.175720_bib21","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2337\/diacare.24.11.1917","article-title":"Changes in BMI and weight before and after the development of type 2 diabetes","volume":"24","author":"Looker","year":"2001","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ejphar.2023.175720_bib22","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00210-022-02243-1","article-title":"Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction","volume":"395","author":"Ma","year":"2022","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.175720_bib23","series-title":"Biochemical Pharmacology","article-title":"\u201cUpregulation of PKR pathway mediates glucolipotoxicity induced diabetic cardiomyopathy in Vivo in Wistar Rats and in Vitro in cultured cardiomyocytes\u201d","author":"Mangali","year":"2020"},{"issue":"16","key":"10.1016\/j.ejphar.2023.175720_bib24","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","article-title":"Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure","volume":"136","author":"Packer","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ejphar.2023.175720_bib25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4093\/dmj.2015.39.5.353","article-title":"Interaction between glucose and lipid metabolism: more than diabetic dyslipidemia","volume":"39","author":"Parhofer","year":"2015","journal-title":"Diabetes Metabol. J."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175720_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-017-0511-0","article-title":"Effects of canagliflozin, a sodium glucose Co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis","volume":"16","author":"Pfeifer","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2023.175720_bib27","doi-asserted-by":"crossref","DOI":"10.1007\/s10741-021-10200-y","article-title":"Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants","author":"Prandi","year":"2022","journal-title":"Heart Fail. Rev."},{"issue":"10","key":"10.1016\/j.ejphar.2023.175720_bib28","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.ejphar.2023.175720_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4196\/kjpp.2018.22.5.493","article-title":"The combination of canagliflozin and omega-3 fatty acid ameliorates insulin resistance and cardiac biomarkers via modulation of inflammatory cytokines in type 2 diabetic rats","volume":"22","author":"Safhi","year":"2018","journal-title":"Korean J. Physiol. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175720_bib30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jphs.2019.11.001","article-title":"Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice","volume":"142","author":"Sawa","year":"2020","journal-title":"J. Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175720_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-016-0456-8","article-title":"Current perspectives on cardiovascular outcome trials in diabetes","volume":"15","author":"Schnell","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175720_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1017\/S0029665107005277","article-title":"High-fat diet, muscular lipotoxicity and insulin resistance","volume":"66","author":"Schrauwen","year":"2007","journal-title":"Proc. Nutr. Soc."},{"issue":"34","key":"10.1016\/j.ejphar.2023.175720_bib33","doi-asserted-by":"crossref","first-page":"861","DOI":"10.5897\/AJPP2015.4396","article-title":"African journal of pharmacy and pharmacology in vitro antioxidant, cytotoxic and phytochemical studies of Clinacanthus Nutans Lindau leaf extracts","volume":"9","author":"Soraya","year":"2015","journal-title":"Afr. J. Pharm. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2023.175720_bib34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.phrs.2005.05.004","article-title":"Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening","volume":"52","author":"Srinivasan","year":"2005","journal-title":"Pharmacol. Res."},{"issue":"7258","key":"10.1016\/j.ejphar.2023.175720_bib35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"Br. Med. J."},{"issue":"6","key":"10.1016\/j.ejphar.2023.175720_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102521","article-title":"Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the MTOR\/HIF-1\u03b1 pathway","volume":"24","author":"Sun","year":"2021","journal-title":"iScience"},{"issue":"September 2020","key":"10.1016\/j.ejphar.2023.175720_bib37","article-title":"Inhibition of SGLT1 protects against glycemic variability-induced cardiac damage and pyroptosis of cardiomyocytes in diabetic mice","volume":"271","author":"Sun","year":"2021","journal-title":"Life Sci."},{"issue":"9","key":"10.1016\/j.ejphar.2023.175720_bib38","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41569-020-0339-2","article-title":"Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence","volume":"17","author":"Tan","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"3","key":"10.1016\/j.ejphar.2023.175720_bib39","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2023.175720_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2018.01575","article-title":"Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients","volume":"9","author":"Uthman","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejphar.2023.175720_bib41","article-title":"Empagliflozin ameliorates diabetic cardiomyopathy via attenuating oxidative stress and improving mitochondrial function","volume":"2022","author":"Wang","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"7","key":"10.1016\/j.ejphar.2023.175720_bib42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4330\/wjc.v6.i7.577","article-title":"Mechanisms underlying the impaired contractility of diabetic cardiomyopathy","volume":"6","author":"Ward","year":"2014","journal-title":"World J. Cardiol."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175720_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0116851","article-title":"Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes","volume":"10","author":"Watanabe","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.175720_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117414","article-title":"Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPAR\u03b1 in vivo and in vitro","volume":"247","author":"Wei","year":"2020","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2023.175720_bib45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13300-020-00951-6","article-title":"Sodium-glucose Co-transporter 2 (SGLT2) inhibitors: are they all the same? A narrative review of cardiovascular outcome trials","volume":"12","author":"Williams","year":"2021","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.ejphar.2023.175720_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117090","article-title":"Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: a mechanistic review","volume":"240","author":"Yaribeygi","year":"2020","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.ejphar.2023.175720_bib47","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","article-title":"Dapagliflozin attenuates Na+\/H+ exchanger-1 in cardiofibroblasts via AMPK activation","volume":"32","author":"Ye","year":"2018","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"5","key":"10.1016\/j.ejphar.2023.175720_bib48","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0042-110934","article-title":"Streptozotocin-treated high fat fed mice: a new type 2 diabetes model used to study canagliflozin-induced alterations in lipids and lipoproteins","volume":"49","author":"Yu","year":"2017","journal-title":"Horm. Metab. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2023.175720_bib49","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jcb.10631","article-title":"Human cardiomyocytes express high level of Na +\/glucose cotransporter 1 (SGLT1)","volume":"90","author":"Zhou","year":"2003","journal-title":"J. Cell. Biochem."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923002315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923002315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T14:42:46Z","timestamp":1736347366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923002315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":49,"alternative-id":["S0014299923002315"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175720","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175720","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175720"}}